Literature DB >> 18272323

Neurocognitive effects of atypical and conventional antipsychotic drugs in schizophrenia: a naturalistic 6-month follow-up study.

Andreas Wittorf1, Stephanie Sickinger, Georg Wiedemann, Stefan Klingberg.   

Abstract

The present study aimed to assess the neurocognitive effects of atypical and conventional antipsychotic drugs on neurocognition under naturalistic treatment conditions. Eighty-two patients with schizophrenia underwent a comprehensive neuropsychological assessment both at baseline during inpatient treatment and 6 months after discharge from hospital (follow-up). From this sample, we selected two subgroups of patients, which had either a continuous atypical (n=33) or conventional (n=16) antipsychotic medication. Twenty-seven out of 40 healthy controls were also retested to control for practice effects. Both patient groups showed a moderate and significant improvement in global cognitive functioning. The repeated measurement ANOVAs revealed no differential treatment effects for all neuropsychological domains. These results remained after controlling for potential confounders between groups. Administering antipsychotic medications in an individually optimized manner seems to have the potential to improve some aspects of neurocognition in schizophrenia, regardless of the kind of antipsychotic medication.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18272323     DOI: 10.1016/j.acn.2007.12.005

Source DB:  PubMed          Journal:  Arch Clin Neuropsychol        ISSN: 0887-6177            Impact factor:   2.813


  4 in total

Review 1.  [Treatment of cognitive deficits in schizophrenia. Part 2: Pharmacological strategies].

Authors:  D Roesch-Ely; U Pfueller; C Mundt; U Müller; M Weisbrod
Journal:  Nervenarzt       Date:  2010-05       Impact factor: 1.214

2.  Neurocognitive outcomes in the Treatment of Early-Onset Schizophrenia Spectrum Disorders study.

Authors:  Jean A Frazier; Anthony J Giuliano; Jacqueline L Johnson; Lauren Yakutis; Eric A Youngstrom; David Breiger; Linmarie Sikich; Robert L Findling; Jon McClellan; Robert M Hamer; Benedetto Vitiello; Jeffrey A Lieberman; Stephen R Hooper
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2012-03-13       Impact factor: 8.829

3.  The switch from conventional to atypical antipsychotic treatment should not be based exclusively on the presence of cognitive deficits. A pilot study in individuals with schizophrenia.

Authors:  Gabriel Selva-Vera; Vicent Balanzá-Martínez; José Salazar-Fraile; José Sánchez-Moreno; Anabel Martinez-Aran; Patricia Correa; Eduard Vieta; Rafael Tabarés-Seisdedos
Journal:  BMC Psychiatry       Date:  2010-06-15       Impact factor: 3.630

4.  Neurocognition in Kenyan youth at clinical high risk for psychosis.

Authors:  Daniel Mamah; Victoria N Mutiso; David M Ndetei
Journal:  Schizophr Res Cogn       Date:  2021-05-25
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.